Histone Hyperacetylation Induced by Histone Deacetylase Inhibitors Is Not Sufficient to Cause Growth Inhibition in Human Dermal Fibroblasts

• Published in: The Journal of biological chemistry Vol. 276; no. 25; pp. 22491 - 22499
• Main Authors: Brinkmann, Hannah, Dahler, Alison L., Popa, Claudia, Serewko, Magdalena M., Parsons, Peter G., Gabrielli, Brian G., Burgess, Andrew J., Saunders, Nicholas A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 22.06.2001; American Society for Biochemistry and Molecular Biology
• Subjects: Acetylation; Cells, Cultured; Enzyme Inhibitors - pharmacology; Fibroblasts - drug effects; Fibroblasts - enzymology; Histone Deacetylase Inhibitors; Histone Deacetylases - genetics; Histone Deacetylases - metabolism; histones; Histones - metabolism; Humans; RNA, Messenger - metabolism; Skin - cytology; Skin - drug effects; Skin - enzymology; suberic bishydroxamate
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M100206200

Use of specific histone deacetylase inhibitors has revealed critical roles for the histone deacetylases (HDAC) in controlling proliferation. Although many studies have correlated the function of HDAC inhibitors with the hyperacetylation of histones, few studies have specifically addressed whether the accumulation of acetylated histones, caused by HDAC inhibitor treatment, is responsible for growth inhibition. In the present study we show that HDAC inhibitors cause growth inhibition in normal and transformed keratinocytes but not in normal dermal fibroblasts. This was despite the observation that the HDAC inhibitor, suberic bishydroxamate (SBHA), caused a kinetically similar accumulation of hyperacetylated histones. This cell type-specific response to SBHA was not due to the inactivation of SBHA by fibroblasts, nor was it due to differences in the expression of specific HDAC family members. Remarkably, overexpression of HDACs 1, 4, and 6 in normal human fibroblasts resulted in cells that could be growth-inhibited by SBHA. These data suggest that, although histone acetylation is a major target for HDAC inhibitors, the accumulation of hyperacetylated histones is not sufficient to cause growth inhibition in all cell types. This suggests that growth inhibition, caused by HDAC inhibitors, may be the culmination of histone hyperacetylation acting in concert with other growth regulatory pathways.